Literature DB >> 24183847

Transgenic expression of GM-CSF in T cells causes disseminated histiocytosis.

Annemarie E van Nieuwenhuijze1, Elise Coghill1, Daniel Gray2, Sandro Prato3, Donald Metcalf4, Warren S Alexander4, Ian P Wicks5.   

Abstract

Recent studies highlight surprising roles for granulocyte-macrophage colony-stimulating factor (GM-CSF) production by T cells. T-cell-derived GM-CSF is required for the differentiation of monocyte-derived inflammatory dendritic cells during inflammation and for the pathogenicity of IL-17 producing T helper cells in autoimmunity. To gain further insight into these findings, we engineered in vivo overexpression of GM-CSF specifically in T cells, under the control of the Lck promoter. Lck-GM-CSF transgenic mice displayed a dramatic phenotype, characterized by splenomegaly, lymphadenopathy, thymic atrophy, and multiple abnormalities in blood cell populations. Thymocyte differentiation was severely affected, and there was a dramatic increase in regulatory T cells in the thymus and peripheral lymphoid organs. Lck-GM-CSF transgenic mice developed a disseminated histiocytosis and had increased circulating IL-17 producing T helper cells-related cytokines. The pathological characteristics in Lck-GM-CSF transgenic mice resemble those of histiocytic human diseases, such as Langerhans cell histiocytosis. The etiology of many histiocytic disorders is unknown, but our findings suggest that over-production of GM-CSF by T cells could be a pathogenic factor and raise the possibility that GM-CSF may represent a novel therapeutic target.
Copyright © 2014 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24183847     DOI: 10.1016/j.ajpath.2013.09.014

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  13 in total

Review 1.  [Pulmonary Langerhans cell histiocytosis].

Authors:  H H Popper
Journal:  Pathologe       Date:  2015-09       Impact factor: 1.011

Review 2.  Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases.

Authors:  John A Hamilton; Andrew D Cook; Paul P Tak
Journal:  Nat Rev Drug Discov       Date:  2016-12-29       Impact factor: 84.694

Review 3.  GM-CSF: A Double-Edged Sword in Cancer Immunotherapy.

Authors:  Anil Kumar; Adeleh Taghi Khani; Ashly Sanchez Ortiz; Srividya Swaminathan
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

Review 4.  Targeting GM-CSF in inflammatory diseases.

Authors:  Ian P Wicks; Andrew W Roberts
Journal:  Nat Rev Rheumatol       Date:  2015-12-03       Impact factor: 20.543

5.  Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis.

Authors:  Annemarie E M van Nieuwenhuijze; Fons A van de Loo; Birgitte Walgreen; Miranda Bennink; Monique Helsen; Liduine van den Bersselaar; Ian P Wicks; Wim B van den Berg; Marije I Koenders
Journal:  Arthritis Res Ther       Date:  2015-06-17       Impact factor: 5.156

Review 6.  Estrogen Receptor-Dependent Regulation of Dendritic Cell Development and Function.

Authors:  Sophie Laffont; Cyril Seillet; Jean-Charles Guéry
Journal:  Front Immunol       Date:  2017-02-10       Impact factor: 7.561

7.  Harnessing RNA sequencing for global, unbiased evaluation of two new adjuvants for dendritic-cell immunotherapy.

Authors:  Till S M Mathan; Johannes Textor; Annette E Sköld; Inge Reinieren-Beeren; Tom van Oorschot; Mareke Brüning; Carl G Figdor; Sonja I Buschow; Ghaith Bakdash; I Jolanda M de Vries
Journal:  Oncotarget       Date:  2017-03-21

8.  GM-CSF Quantity Has a Selective Effect on Granulocytic vs. Monocytic Myeloid Development and Function.

Authors:  Li Sun; Jai Rautela; Rebecca B Delconte; Fernando Souza-Fonseca-Guimaraes; Emma M Carrington; Robyn L Schenk; Marco J Herold; Nicholas D Huntington; Andrew M Lew; Yuekang Xu; Yifan Zhan
Journal:  Front Immunol       Date:  2018-08-28       Impact factor: 7.561

9.  Posttransplant Hemophagocytic Lymphohistiocytosis Driven by Myeloid Cytokines and Vicious Cycles of T-Cell and Macrophage Activation in Humanized Mice.

Authors:  Satoshi Yoshihara; Yuying Li; Jinxing Xia; Nichole Danzl; Megan Sykes; Yong-Guang Yang
Journal:  Front Immunol       Date:  2019-02-13       Impact factor: 7.561

10.  Development of Mast Cell and Eosinophil Hyperplasia and HLH/MAS-Like Disease in NSG-SGM3 Mice Receiving Human CD34+ Hematopoietic Stem Cells or Patient-Derived Leukemia Xenografts.

Authors:  Laura J Janke; Denise M Imai; Heather Tillman; Rosalinda Doty; Mark J Hoenerhoff; Jiajie J Xu; Zachary T Freeman; Portia Allen; Natalie Wall Fowlkes; Ilaria Iacobucci; Kirsten Dickerson; Charles G Mullighan; Peter Vogel; Jerold E Rehg
Journal:  Vet Pathol       Date:  2020-11-19       Impact factor: 2.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.